MDxHealthMDXH -6.12%45 FCF Margin % is -6.77% as of Mar. 2026. GuruFocus rates MDXH with a GF Score™ of 45/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, MDxHealth ranks worse than 50.49% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MDxHealth's Free Cash Flow for the
three
months ended in Mar. 2026 was $-1.9 Mil. MDxHealth's Revenue for the
three
months ended in Mar. 2026 was $27.4 Mil. Therefore, MDxHealth's FCF Margin % for the quarter that ended in Mar. 2026 was -6.77%.
The historical rank and industry rank for MDxHealth's FCF Margin % or its related term are showing as below:
MDXH'
s FCF Margin % Range Over the Past 10 Years
Min: -189.75 Med: -87.6 Max: -1.89
Current: -1.89
During the past 13 years, the highest FCF Margin % of MDxHealth was -1.89%. The lowest was -189.75%. And the median was -87.60%.
MDXH's FCF Margin % is ranked worse than 50.49% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs MDXH: -1.89
MDxHealth FCF Margin % Related Terms
MDxHealth FCF Margin % Historical Data
* Premium members only.
The historical data trend for MDxHealth's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, MDxHealth's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MDxHealth FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's FCF Margin % distribution charts can be found below:
* The bar in red indicates where MDxHealth's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDxHealth (MDXH) has a FCF Margin % of -6.77% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MDxHealth and its competitors. According to the industry distribution chart, MDxHealth ranks #103 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 50.5%.
Is MDxHealth's FCF Margin % too high?
MDxHealth's current FCF Margin % is -6.77%. Based on the distribution chart, MDxHealth ranks #103 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, MDxHealth has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's FCF Margin % compare to PRPO and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, MDxHealth ranks #103 out of 204 companies for FCF Margin %. This places MDxHealth in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MDxHealth and its competitors. MDxHealth's current FCF Margin % is -6.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.44 — trading 79.8% below its estimated fair value. The current FCF Margin % is -6.77%. MDxHealth's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For MDxHealth (MDXH), the current FCF Margin % is -6.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MDxHealth (MDXH) Overvalued in 2026?
Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued.
The current stock price of $0.44 is trading 79.8% below its estimated GF Value™ of $2.20.
GuruFocus considers MDxHealth to be Possible Value Trap.
Key valuation signals for MDXH:
FCF Margin %: -6.77%
GF Value™: $2.20 vs. price of $0.44 (79.8% below fair value)
No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
45GF Score
Get the complete analysis for MDXH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXH has been successfully added to your 
